Biocracked
Approach: the human outcome. Palette: C, natural.

A low-angle, side-on close shot of a sprinter's lower legs and spiked shoes at the start of a worn terracotta-red running track, just after sunrise. Low golden daylight rakes across the lane lines and picks out the sweat on the calf muscles and the tendons in the ankle. Behind the athlete, soft-focus green grass and a line of trees fill the background. The runner's face is out of frame. A single electric-green shoelace on one spiked shoe is the only accent. The depth of field is shallow, with the foreground track grain crisp and the background creamy. The mood is quiet and determined, with natural skin tones, earthy reds, and fresh greens. No blue cast, no text, no logos.
Peptides

Athletes Have 59% More MOTS-c Before Anyone Injects a Thing

Helix Ward · · 5 min read

Before you buy a vial of the "exercise mimetic" peptide, consider this: a small new study found that elite sprinters and field athletes already carry about 59% more circulating MOTS-c than sedentary young men, and nobody gave them an injection.

The finding comes from a cross-sectional study in Antioxidants (Zhang et al., 2026) from Tianjin University of Sport. It is a small snapshot of 30 people, not a trial. It still adds a useful data point to a peptide that is often marketed as a shortcut to what training already does.

What is MOTS-c?

MOTS-c is a short peptide encoded in mitochondrial DNA rather than the nuclear genome. It belongs to the "mitochondrial-derived peptides," which are described as signaling molecules, or mitokines. The authors call it an exercise-responsive mitokine, meaning its levels appear to shift with physical activity. Its link to metabolism and exercise is why it has picked up the "exercise mimetic" label in online peptide circles.

The paper's own framing is more modest. The authors say the associations between MOTS-c, exercise capacity and antioxidant markers "remain unclear," and that is the gap they set out to address.

The three groups

The researchers recruited 30 healthy males aged 18 to 25 and split them into three groups of 10:

  • Elite track and field athletes
  • Recreationally active individuals
  • Sedentary controls

They measured serum MOTS-c alongside superoxide dismutase (SOD, an antioxidant enzyme) and post-exercise malondialdehyde (MDA, a common marker of oxidative damage to lipids). They also ran a battery of fitness tests: VO2max, forced vital capacity, vertical jump, handgrip strength, back muscle endurance and post-fatigue back muscle force.

The numbers

MOTS-c rose step by step with fitness level:

Group Serum MOTS-c (pg/mL)
Elite athletes 507.51 ± 67.42
Recreationally active 440.32 ± 32.83
Sedentary 319.31 ± 99.07

The difference was statistically significant (p < 0.001). The athlete-versus-sedentary comparison had a Hedges' g of 2.13, a very large effect size. The "59%" figure is simply the athlete average divided by the sedentary average. The active group sat in the middle, roughly 38% above sedentary by the same arithmetic.

What tracked with MOTS-c

Across the whole sample, MOTS-c correlated strongly with several measures (all p < 0.001):

  • Absolute VO2max: r = 0.892
  • SOD: r = 0.847
  • Post-exercise MDA: r = −0.910, so higher MOTS-c went with less oxidative damage after exercise
  • Back muscle endurance: r = 0.725
  • Post-fatigue back muscle force: r = 0.812

Handgrip strength was the exception. It showed no significant correlation (r = 0.315, p = 0.090). The pattern points more toward endurance and fatigue-related capacity than raw grip strength, though with this sample size that is a tentative reading.

In an exploratory hierarchical regression, post-exercise MDA stayed significantly associated with MOTS-c after adjusting for VO2max. SOD did not. So the link between MOTS-c and lower oxidative damage may not be explained by aerobic fitness alone, but the authors label this analysis exploratory.

Limits you need to know

This is where the headline needs to be read carefully.

  • Cross-sectional design. Everyone was measured once. The authors state plainly that the design "precludes causal inference." We cannot say training raised MOTS-c, that high MOTS-c made people fitter, or that something else (genetics, diet, training history) drives both.
  • Tiny sample. Ten people per group, all young males. The findings say nothing definitive about women, older adults or people with metabolic disease.
  • Wide spread in the sedentary group. Its standard deviation (about 99 pg/mL) is large, so individual values overlap and group averages hide a lot.
  • Circulating levels only. The study measured natural serum MOTS-c. It tested no injected peptide, no doses and no timing.
  • Correlation is not mechanism. Strong r values in 30 people can be inflated by comparing extreme groups such as elite athletes and sedentary controls.

Takeaways

1. Training is associated with higher MOTS-c in your own body. The most defensible reading is that fitter people in this sample had higher endogenous MOTS-c. If MOTS-c is part of how exercise benefits the body, you may already be producing more of it by training. This study cannot prove that, but it fits the "exercise-responsive" description.

2. This study gives no basis for dosing or timing. The paper has no dosing, injection schedule or intervention data. Any dose or timing protocol you see online cannot be drawn from this work. Anyone wanting to know whether injected MOTS-c does anything in humans needs controlled trials, which this is not. Animal and lab studies on the peptide are preclinical background and shouldn't be assumed to carry over to people.

3. Who is this for? Based on the evidence here, nobody in particular. The study is descriptive and does not identify a group that should use the peptide. Higher natural levels in athletes do not show that raising levels artificially would give non-athletes the same benefits. Athletes' MOTS-c was embedded in a whole physiology shaped by years of training.

4. Regulatory context (not from the paper). The study says nothing about legal status. To my knowledge MOTS-c is not an approved medicine, but check current regulatory status yourself. Competitive athletes should not assume it is permitted and should check the current WADA Prohibited List or ask their anti-doping organization before using any research peptide. I cannot confirm from the source how it is currently listed.

5. The practical bottom line. Aerobic fitness showed the clearest relationship with MOTS-c here, and VO2max is something you can train. Regular exercise is a well-established way to improve it, with no injection required.

The bigger picture

The study fits a growing view that mitochondria send signals that coordinate whole-body metabolism, and that exercise changes those signals. What it cannot do is show that adding the signal from outside reproduces the effect of the training behind it. The most useful next steps would be longitudinal studies that track MOTS-c as people begin training, and randomized trials in larger and more diverse groups. Until then, the 59% figure is better read as a measure of how different athletes' biology is than as a case for supplementation.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

HW

Written by

Helix Ward

Helix Ward writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: the human outcome. Palette: warm, golden-hour light.

A woman in her fifties seen from behind and slightly above, in a low lunge on a yoga mat. Her face is out of frame, and only her shoulders, outstretched arms and tied-back silver-brown hair show. She practices on a wooden floor beside a tall window as low amber sunlight rakes across the room. The light picks out the weave of her rust-colored top and the fine skin texture of her forearms. In the foreground, a small glass dish of deep red-orange astaxanthin softgels sits slightly out of focus on the floor, catching a copper glow. A single small electric green water bottle sits at the edge of the mat. Shot at 35mm with shallow depth of field, in warm honey tones with soft brown shadows. The mood is calm, grounded and quietly hopeful.
supplements

Yoga + Astaxanthin Cut Depression Scores 45%. Alone, Far Less

BY NOVA CHEN ·

A 12-week randomized trial in 100 postmenopausal women found that combining Hatha yoga with 12 mg/day of astaxanthin cut depression scores by 45.1%. Yoga alone managed 28.5%, and astaxanthin alone just 10.9%. The combination also improved menopause symptoms, antioxidant enzyme activity and NRF1 expression, while SIRT1 and PGC-1α rose in both yoga arms. But the study is small, likely single-center and limited to women with mild-to-moderate symptoms. Here's what the numbers show, what they don't, and who the stack might suit.

Approach: Macro science. Palette: D, bold color field.

Extreme close-up microscopy-style photograph of a stained rat skeletal muscle cross-section, shot straight down through the microscope objective. Polygonal muscle fibers fill the frame in saturated magenta and pink eosin tones. A cluster of fibers on the left is neatly packed and uniform. On the right, the tissue is disrupted, with swollen gaps and thin, fibrous collagen strands in pale violet threading between damaged cells. A few tiny electric green fluorescent specks sit along one fiber edge as a subtle accent. Lighting is bright, even transmitted light with crisp focus at the center and soft falloff at the edges. The mood is analytical and tense, a rescue only partly complete. No text, no labels.
peptides

BPC-157 Protected Rat Muscle From Blood-Flow Injury—With a Catch

BY NOVA CHEN ·

Cut off blood flow to a muscle and then restore it, and the comeback itself can do serious damage. A new rat study found that BPC-157 given at the end of ischemia was linked to lower oxidative stress, less apoptosis signaling, less inflammation and partial recovery of VEGF. Tissue staining also showed better muscle structure and less collagen buildup. But the study used just 6 rats per group, one intraperitoneal dose of 20 µg/kg and only 2 hours of reperfusion. BPC-157 is not an approved drug, and this is animal-only research that doesn't justify human use.

Approach: conceptual metaphor. Palette: bold color field.

A single oversized brass balance scale sits on a saturated tomato-red seamless backdrop, photographed at a low three-quarter angle. One pan holds a small, glowing ember-orange coal that is cooling and dimming to grey ash at its edges, standing for inflammation. The other pan holds a tightly coiled, freshly cut green plant sprout with a tiny electric green (#00e676) tip, standing for repair and growth. The scale tips slightly toward the ember, leaving the viewer unsure which side is better. Hard but clean studio key light from upper left casts a crisp, graphic shadow across the red surface. Brass shows real fingerprints and fine scratches, and the ash has a visible powdery texture. The mood is tense, thoughtful and questioning, with the whole image shot at shallow depth of field and the fulcrum in sharp focus. No text, no markings on the scale.
supplements

NMN Calms Muscle Inflammation After Training—But at What Cost?

BY NOVA CHEN ·

NMN is sold as a cellular-energy booster, but a new muscle-biopsy study found a surprising tradeoff. After a damaging blood flow restriction workout, 1,200 mg/day of NMN suppressed inflammatory signals like TNF-α and IL-10. It also delayed a repair-related marker and erased the 171% mitochondrial increase seen with placebo. The study is tiny (11 untrained young men), so it can't settle anything. It does challenge the assumption that less post-workout inflammation is always better.

**Approach: Lab in action. Palette: D, bold color field (teal).**

Overhead three-quarter angle on a gloved hand holding a small insulin-style syringe over a tray of mouse-muscle tissue samples. The nitrile glove is bright white, and the backdrop is a saturated teal lab bench surface with a soft sheen. Tiny clear microtubes sit in a rack, and a few contain a faint amber liquid. One thin electric green cap on a tube is the only green accent. The lighting is bright, even studio-like lab light with crisp, soft-edged shadows and a gentle highlight on the syringe barrel and a single hanging droplet at the needle tip. The depth of field is shallow, so the background tubes blur into teal. The mood is precise, focused and quietly hopeful, with no readable text or labels anywhere.
peptides

One Shot Made Old Mouse Muscle Mitochondria Act Young in 1 Hour

BY HELIX WARD ·

A single injection of SS-31 (elamipretide) restored muscle mitochondrial energy production in very old mice to young levels within one hour. That result comes from a 2013 mouse study, not from human trials. The peptide had no observable effect on young muscle, and eight days of treatment improved endurance in the old animals. In humans, elamipretide won FDA accelerated approval for Barth syndrome but missed its primary endpoints in the MMPOWER-3 mitochondrial myopathy trial. Here is what the study showed, where it falls short, and why grey-market versions are a bad idea.

This page is available in